ESTRO 2024 - Abstract Book

S189

Brachytherapy - GI, paediatric, miscellaneous

ESTRO 2024

differentiated carcinoma, heavy nodal burden and type IV HCCA. The location of recurrence was liver + nodes in one patient and cut surface near the anastomosis + liver in another patient (in spite of EBRT). Local control at the anastomotic site was 80%. The median and mean disease-free interval from the time of brachytherapy was 12 and 12.8 (R: 5 – 19) months respectively. At median duration of 17 months from brachytherapy, no patient has suffered late stricture requiring dilation of Hep-J.

Conclusion:

Post-operative intraluminal brachytherapy for resected margin positive Hilar Cholangiocarcinoma appears to be a safe, without acute or late toxicity. It does not delay adjuvant chemotherapy nor necessitates chemotherapy dose reduction. With a local control of 80%, this simple procedure helps reduce local progression among margin positive HCCAs.

Keywords: Intraluminal, Hilar Cholangiocarcinoma, Adjuvant

References:

1. Tang Z, Yang Y, Zhao Z, Wei K, Meng W, Li X (2018). The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: a systematic review and meta-analysis. Medicine 97(34):p e11999, August 2018. | DOI: 10.1097/MD.0000000000011999.

2. Endo I., House MG, Klimstra DS, Gonen M, D'angelica M, De Matteo R, et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol. 2008; 15:2014-2112.

3. Yohanathan L, Croome KP, Traynor M, Puig CA, Mara KC, Cleary SP et al. Significance of proximal ductal margin status after resection of hilar cholangiocarcinoma. HPB (Oxford). 2021 Jan;23(1):109-117. doi: 10.1016/j.hpb.2020.05.002. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary tract cancers V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [Oct 23rd,2023].

2565

Mini-Oral

Clinical prediction models for contact brachytherapy in managing rectal cancers: A scoping review

Muneeb U Haq 1,2 , David M Hughes 3 , Arthur S Myint 4 , Carrie Duckworth 1 , David M Pritchard 1 , Laura J Bonnett 3

1 The University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Liverpool, United Kingdom. 2 The Clatterbridge Cancer Centre NHS Foundation Trust,, Brachytherapy Department, Liverpool, United Kingdom. 3 The University of Liverpool, Institute of Population Health, Liverpool, United Kingdom. 4 The Clatterbridge Cancer Centre NHS Foundation Trust, Brachytherapy Department, Liverpool, United Kingdom

Purpose/Objective: